Recce Pharmaceuticals Ltd
RECEF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $1 | $7 | $0 | $2 |
| % Growth | -91.9% | – | -100% | – |
| Cost of Goods Sold | $2 | $8 | $0 | $0 |
| Gross Profit | -$1 | -$1 | -$0 | $2 |
| % Margin | -265.4% | -20.8% | – | 91.9% |
| R&D Expenses | $2 | $8 | $0 | $5 |
| G&A Expenses | $7 | $1 | $1 | $1 |
| SG&A Expenses | $5 | $5 | $12 | $9 |
| Sales & Mktg Exp. | -$2 | $4 | $1 | $8 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7 | $13 | $12 | $9 |
| Operating Income | -$8 | -$14 | -$12 | -$10 |
| % Margin | -1,498.2% | -208.1% | – | -403.4% |
| Other Income/Exp. Net | -$5 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$14 | -$14 | -$13 | -$10 |
| Tax Expense | $0 | -$7 | -$3 | -$2 |
| Net Income | -$14 | -$8 | -$10 | -$7 |
| % Margin | -2,434.2% | -111.4% | – | -313.3% |
| EPS | -0.056 | -0.034 | -0.05 | -0.042 |
| % Growth | -65.4% | 32.4% | -20.2% | – |
| EPS Diluted | -0.056 | -0.034 | -0.05 | -0.042 |
| Weighted Avg Shares Out | 245 | 229 | 204 | 179 |
| Weighted Avg Shares Out Dil | 245 | 229 | 204 | 179 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$13 | -$7 | -$12 | -$9 |
| % Margin | -2,363.7% | -100.6% | – | -389.5% |